Onkologie. 2014:8(1):28-33

New options in the treatment of myelodysplastic syndromes

Eva Kadlčková1, Peter Rohoň2
1 Hematologicko-transfuzní oddělení Krajské nemocnice T. Bati Zlín
2 Hematoonkologická klinika FN a LF UP Olomouc

Myelodysplastic syndromes (MDS) are heterogeneous group of clonal hematopoietic stem cell disorders characterized by dysplastic

changes of bone marrow precursors, peripheral (pan) cytopenias and an increased risk of progression to acute myeloid leukemia (AML).

Two basic therapeutic approaches were used in the treatment of MDS: supportive care or allogeneic stem cell transplantation (ASCT).

Nowadays the treatment options for MDS patients has significantly expanded. In addition to conventional treatment there are new drugs

and their combinations which may affect the natural history of the disease and prolong survival. In the clinical practice hypometylating

agents, immunomodulatory drug lenalidomide (LEN) and modern chelators are used.

Keywords: myelodysplastic syndromes, hypometylating agents, immune modulation, iron chelators

Published: March 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kadlčková E, Rohoň P. New options in the treatment of myelodysplastic syndromes. Onkologie. 2014;8(1):28-33.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. List AF, Vardiman J, Issa JP, et al. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2004: 297-317. Go to original source... Go to PubMed...
    2. Rollinson DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from NAACCR and SEER programs.Blood 2008; 112: 45-52. Go to original source... Go to PubMed...
    3. Greenberg PL, Cox C, Le Beau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088. Go to original source...
    4. Greenberg PL, Tuechler H, Schanz J, et al. Revised international scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454-2465. Go to original source... Go to PubMed...
    5. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503-3510. Go to original source... Go to PubMed...
    6. Neuwirtová R, Jonášová A, Voglová J, a kol. Myelodysplastický syndrom a jeho léčba. Farmakoterapie. 2010, roč. 6, speciální příloha - červen 2010: 16-22. ISSN 1801-1209.
    7. Stone RM. How I treat patient with myelodysplastic syndroms. Blood 2009; 113: 6296-6303. Go to original source... Go to PubMed...
    8. Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009; 113: 1315-1325. Go to original source... Go to PubMed...
    9. Weber M, Hellmann I, Stadler MB, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007; 39: 457-466. Go to original source... Go to PubMed...
    10. Issa JP. Epigenetic changes in the myelodysplastic syndrome. Hematol Oncol Clin North Am 2010: 317-330. Go to original source... Go to PubMed...
    11. da Rocha ST, Ferguson-Smith AC. Genomic imprinting. Curr Biol 2004; 14: 646-649. Go to original source... Go to PubMed...
    12. Esteller M. DNA methylation and cancer therapy: new developments and expectations. Curr Opin Oncol 2005; 17: 55-60. Go to original source... Go to PubMed...
    13. Sorm F, Piskala A, Cihak A, et al. 5-Azacytidine, a new, highly effective cancerostatic. Experientia 1964; 20:202-203. Go to original source... Go to PubMed...
    14. Issa JP, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res 2009; 15: 3938-3946. Go to original source... Go to PubMed...
    15. Kuykendall JR. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders. Ann Pharmacother 2005; 39: 1700-1709. Go to original source... Go to PubMed...
    16. Bontkes HJ, Ruben JM, Alhan C, et al. Azacitidine differentially affects CD4pos T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromes. Leuk Res 2012; 36: 921-930. Go to original source... Go to PubMed...
    17. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higherrisk myelodysplastic syndromes: a randomized, open-label, phase III study. Lancet Oncol 2009; 10: 223-232. Go to original source... Go to PubMed...
    18. Seymour JF, Fenaux P, Silverman LR, et al. Effects of azacitidine compared with conventional care regimens in elderly (75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 2010; 76: 218-227. Go to original source... Go to PubMed...
    19. Field T, Perkins J, Huang Y, et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2010; 45: 255-260. Go to original source... Go to PubMed...
    20. Gerds AT, Gooley TA, Estey EH, et al. Pretransplantation therapy with azacitidine vs.induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant 2012; 18: 1211-1218. Go to original source... Go to PubMed...
    21. Maurillo L, Venditti A, Spagnoli A, et al. Azacitidine for the treatment of patients with acute myeloid leukemia, Cancer 2012; 118: 1014-1022. Go to original source... Go to PubMed...
    22. Costa R, Abdulhaq H, Haq B, et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer 2010; 117: 2690-2696. Go to original source... Go to PubMed...
    23. Kantarjian H, Oki Y, Garcia-Maneiro G, et al. Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52-57. Go to original source... Go to PubMed...
    24. Komrokji RS, List A. Lenalidomide for treatment of myelodysplastic syndromes. Curr Pharm Des 2012; 18: 3198-3203. Go to original source... Go to PubMed...
    25. Kuendgen A, Lauseker M, List AM, et al. Lenalidomid treatment is not related to AML progression risk but is associated with survival benefit in RBC-dependent transfusion patients with IPSS Low- or Int 1-Risk MDS with del5q. Blood 2011; 118. Abstract 119. Go to original source... Go to PubMed...
    26. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456-1465. Go to original source... Go to PubMed...
    27. Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009; 2: 36-42. Go to original source... Go to PubMed...
    28. Giagounidis AA. Lenalidomide for del (5q) and non-del (5q) myelodysplastic syndromes. Semin Hematol 2012; 49: 312-322. Go to original source... Go to PubMed...
    29. Komrokji RS, List AF. Lenalidomide for Treatment of Myelodysplastic Syndromes: Current Status and Future Directions. Hematology/Onkology Clinics of North America: Myelodysplastic Syndromes. Philadelphia: Saunders an imprint of Elsevier, Inc., 2010; 24 (2). ISSN 0889-8588. Go to original source...
    30. Ades L, Boehres S, Prebet T, et al. Efficacy and safety of lenalidomide in intermediate-2 or high risk myelodysplastic syndrome with 5q del: results of a phase 2 study. Blood 2009; 113: 3947-3952. Go to original source... Go to PubMed...
    31. Ebert BL, Galili N, Tamayo P, et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 2008; 5 (2): e35. Go to original source... Go to PubMed...
    32. Sekeres MA, List AF, Cuthbertson D, et al. Phase I combination trial of lenalidomide and azacytidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol 2010; 28: 2253-2258. Go to original source... Go to PubMed...
    33. Venner CP, Woltosz JW, Nevill TJ, et al. Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34+ cells from patients with del (5q) myelodysplastic syndrome. Haematologica 2013; 98: 409-413. Go to original source... Go to PubMed...
    34. Horváthová M, Pospíšilová D. Nové poznatky o homeostáze železa a jejich důsledky pro klinickou praxi. Postgraduální medicína. 2010; 12 (6): 676-681. ISSN 1212-4184.
    35. Čermák J. Přetížení železem-novinky v patogenezi a léčbě. Vnitřní lékařství: 90 let doc. MUDr. Dušana Mrkose, CSc., XXVIII. dny mladých internistů - sborník abstrakt. 2009; 55 (1): 59-63. ISSN 0042-773X.
    36. Pospíšilová D. Současný přístup k léčbě přetížení železem. Farmakoterapie. 2010; 6 (1): 84-90. ISSN 1801-1209.
    37. Penka M, Buliková A. Neonkologická hematologie: 2.doplněné a zcela přepracované vydání. 2. vyd. Praha: Grada Publishing, 2009: 25-38. ISBN 978-80-247-2299-3.
    38. Kyselá J, Jonášová A. Chelatační léčba deferasiroxem u pacientů s myelodysplastickým syndromem s přetížením železem-výsledky observačních studií eXtend a eXjange: komentář ke studii. Farmakoterapie. 2012; 8 (3): 349-352. ISSN 1801-1209.
    39. Rose C, Brechignac S, Vassilief D, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies).Leukemia Research, Jul 2010,34 (7): 864-70 www.elsevier.com/locate/leukres. Go to original source... Go to PubMed...
    40. Jessica Langholtz: Hepcidin Levels Differ Markedly Among MDS Subtypes, The MDS Beacon.
    41. Kazuki T, Keiki K, Fumihiko N, et al. The effect of iron overload and chelation on erythroid differentiation. International Journal of Hematology. 2012, roč. 95, č. 2, s. 149-159. ISSN 0925-5710. DOI: 10.1007/s12185-011-0988-3. Copyright: The Japanese Society of Hematology 2012. Go to original source... Go to PubMed...
    42. Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586-4588. Go to original source... Go to PubMed...
    43. Pullarkat V, Blanchard S, Tegtmeier B, et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2008; 42: 799-805. Go to original source... Go to PubMed...
    44. Čermák J. Myelodysplastický syndrom: Chelatační terapie. Transfuze a hematologie dnes: Doporučené postupy v hematologii supplementum -2010; 16 (3): 40. ISSN 1213-5763.
    45. Remacha AF, Arrizabalaga B, Del Canizo C, et al. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements. Annals of Hematology, Feb 2010; 89 (2): 147-154. Go to original source... Go to PubMed...
    46. Messa E, Carturan S, Maffe C, Pautasso Marisa, et al. Deferasirox is a powerful NF-?B inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Hematologica. 2010; 95 (8): 1308-1316. ISSN ISSN 0390-6078. DOI: 10.3324/haematol.2009.016824. Go to original source... Go to PubMed...
    47. Bergeron, RJ, Wiegand J, Bharti N, et al. Desferrithiocin analogue iron chelators: iron clearing, efficiency, tissue distribution, and renal toxicity.Biometals. 2011; 24 (2): 239-258. ISSN 0966-0844. DOI: 10.1007/s10534-010-9389-y. Go to original source... Go to PubMed...
    48. Cang S, Ma Y, Liu D. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J Hematol Oncol 2009; 2: 22. Go to original source... Go to PubMed...
    49. Stimson L, Wood V, Khan O, et al. HDAC inhibitor-based therapies and haematological malignancy. Ann Oncol 2009; 20: 1293. Go to original source... Go to PubMed...
    50. Steensma, DP. Novel Therapies for Myelodysplastic Syndromes. Hematology/Onkology Clinics of North America: Myelodysplastic Syndromes. Philadelphia: Saunders an imprint of Elsevier, Inc., 2010; 24 (2). ISSN 0889-8588. Go to original source...
    51. Cutler C. Patient Selection for Transplantation in the Myelodysplastic Syndromes. Hematology/Onkology Clinics of North America: Myelodysplastic Syndromes. Philadelphia: Saunders an imprint of Elsevier, Inc., 2010; 24 (2). ISSN 0889-8588. Go to original source...
    52. Cazzola M, Malcovati L. Prognostic Classification and Risk Assessment in myelodysplastic Syndromes. Hematology/Onkology Clinics of North America: Myelodysplastic Syndromes. Philadelphia: Saunders an imprint of Elsevier, Inc., 2010, roč. 24, č. 2. s. 464. ISSN 0889-8588. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.